%0 Generic
%A Ladehesa, L.
%A Castro, M. G.
%A Lopez-Pedrera, C.
%A Ortega, R.
%A Pedraza, S.
%A del Rio, M.
%A Abalos-Aguilera, M. C.
%A Ruiz-Limon, P.
%A Perez-Sanchez, C.
%A Ibanez-Costa, A.
%A Parra-Manso, Y.
%A Barbarroja, N.
%A Arias-de la Rosa, I.
%A Font, P.
%A Escudero, A.
%A Castano, J. P.
%A Luque, R. M.
%A Collantes, E.
%A Jimenez-Gomez, Y.
%T Altered expression of the spliceosome components in leukocytes subsets from patients with ankylosing spondylitis: association to disease pathogenesis and therapeutic response
%D 2022
%@ 0003-4967
%U https://hdl.handle.net/10668/28325
%X Ankylosing spondylitis (AS) is a chronic inflammatory disease whose etiopathogenesis remains incompletely understood. Splicing, a posttranscriptional process essential for RNA maturation, has recently been implicated in several human diseases through pathological deregulation of the spliceosome; however, alterations of the spliceosome and their modulation by therapeutic responses have not yet been described in AS. The objectives of this study were: (1) to evaluate the potential deregulation of the spliceosome in leukocytes from AS patients and its involvement in disease pathophysiology, and (2) to analyze the in vivo effects of anti-TNF drugs on spliceosome components in these cells. A cross-sectional study was conducted with 32 AS patients and 29 healthy donors (HDs), and a three-month longitudinal study was performed in eight AS patients undergoing anti-TNFα therapy. Disease activity was assessed using the BASDAI index, along with CRP and ESR levels; physical function was measured by BASFI, spinal mobility by BASMI, and structural damage by mSASSS. The expression of selected components of the major (n=12) and minor (n=4) spliceosomes, as well as splicing factors (n=28), was evaluated in purified leukocytes using Fluidigm technology, while inflammatory marker expression was assessed in parallel by RT-PCR.
%K Spondylitis, Ankylosing
%K Spliceosomes
%K Cross-Sectional Studies
%K Tumor Necrosis Factor Inhibitors
%~